Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (XTNT) is a leader in regenerative medicine, specializing in orthobiologics and spinal implant systems for complex surgical procedures. This page aggregates official company news, including product developments, financial updates, and strategic initiatives within the orthopedic and neurological sectors.
Investors and healthcare professionals will find verified press releases covering regulatory milestones, partnership announcements, and advancements in bone healing technologies. Our repository ensures access to timely updates on Xtant Medical's surgical solutions, including spinal fusion devices and biologics designed to improve patient outcomes.
Bookmark this page for direct access to earnings reports, acquisition news, and clinical trial progress. All content is sourced from official channels to maintain accuracy and compliance with financial disclosure standards.
Xtant Medical Holdings reported a 3% revenue increase to $13.0 million for Q1 2022, up from $12.5 million in Q1 2021. The biologics segment saw a notable 13% year-over-year growth, driven by new product launches and expanded distribution. However, gross margin decreased to 58.3% from 64.5% due to higher production costs and a shift in sales mix. Operating expenses rose to $9.4 million, leading to a net loss of $2.2 million, compared to a loss of $29,000 in Q1 2021. Non-GAAP Adjusted EBITDA also worsened to a loss of $0.9 million.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Chief Financial Officer, effective June 1, 2022. Neils, who has over 15 years of experience in public accounting and finance, previously served as the interim CFO since January 3, 2022, and as the company's Controller since August 2019. His extensive experience is expected to support the company’s growth strategy and mission of 'honoring the gift of donation.' The leadership change aims to strengthen financial management amid ongoing challenges in the medical technology sector.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for Q1 2022 on May 5, 2022, before market open. The conference call to discuss these results will be hosted by CEO Sean Browne and Interim CFO Scott Neils at 9:00 AM ET. Investors can access the call via dial-in or webcast. Xtant specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems for complex spine procedures.
Xtant Medical Holdings (NYSE American: XTNT) has announced that its President and CEO, Sean Browne, will present at the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:00 p.m. CT in Chicago. The presentation will focus on the company’s innovative surgical solutions for spinal disorders. Investors can access a live webcast through the company’s website, with a replay available for 90 days post-event. Xtant specializes in orthobiologics and spinal implant systems aimed at enhancing spinal fusion in complex and degenerative procedures.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported financial results for the fourth quarter and full year ended December 31, 2021. The company achieved 4% year-over-year revenue growth, totaling $55.3 million for 2021, driven by private label and OEM orthobiologics sales. The fourth quarter revenue remained stable at $14.0 million. However, gross margin decreased to 55.1% from 64.1% in Q4 2020. Operating expenses rose to $9.6 million in Q4. The net loss for the year improved to $4.8 million, compared to $7.0 million in 2020.
Xtant Medical Holdings (NYSE American: XTNT) will release its financial results for Q4 and the full year ending December 31, 2021, on March 8, 2022, before market open. CEO Sean Browne and Interim CFO Scott Neils will discuss the results in a conference call scheduled for the same day at 9:00 AM ET. Investors can access the call by dialing 877-407-6184 or internationally at 201-389-0877. A replay will be available on their website post-call.
Xtant Medical Holdings, a global medical technology company specializing in spinal disorder solutions, announced that CEO Sean Browne will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A pre-recorded presentation will be available on the company's website starting January 10, 2022, at 7:00 AM Eastern Time and will remain accessible for 30 days. Xtant focuses on designing and commercializing orthobiologics and spinal implant systems for complex spinal procedures.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Interim Chief Financial Officer, effective January 3, 2022. Neils, who has 15 years of experience in public accounting and corporate finance, previously served as the Company’s Controller since August 2019. His promotion follows the tenure of Greg Jensen, who has led the finance team for nearly three years. Neils' extensive experience in finance will be pivotal for the Company as it continues to focus on surgical solutions for spinal disorders, ensuring stability during this transitional phase.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported third quarter 2021 financial results, noting a revenue of $13.8 million, a slight decrease from $14.0 million in the prior-year period. The company experienced a net loss of $1.8 million, up from a loss of $1.4 million year-over-year. Gross margin also declined to 52.2% from 66.0%, attributed to changes in sales mix and increased write-downs of excess inventory. Operating expenses rose to $8.6 million due to higher salaries and marketing costs. Xtant continues to expand its distribution network despite challenges from the COVID-19 delta variant.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its Q3 financial results for the period ending September 30, 2021, on November 12, 2021, prior to market opening. A conference call featuring Sean Browne, President and CEO, and Greg Jensen, CFO, is scheduled for 9:00 AM ET the same day. Investors can listen to the call via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders and offers a range of orthobiologics and spinal implant systems.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
